ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

トリクロロメチアジド

Trichlormethiazide

HCID 5560
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
133-67-5
標準SMILES
NS(=O)(=O)c1cc2c(cc1Cl)NC(C(Cl)Cl)NS2(=O)=O
InChIKey
LMJSLTNSBFUCMU-UHFFFAOYSA-N
分子式
C8H8Cl3N3O4S2
平均分子量
380.7 g/mol
単同位体質量
378.902181

概要

Trichlormethiazide is a benzothiadiazine, hydrogenated at positions 2, 3 and 4 and substituted with an aminosulfonyl group at C-7, a chloro substituent at C-6 and a dichloromethyl group at C-3 and with S-1 as an S,S-dioxide. A sulfonamide antibiotic, it is used as a diuretic to treat oedema (including that associated with heart failure) and hypertension. It has a role as a diuretic and an antihypertensive agent. It is a benzothiadiazine and a sulfonamide antibiotic.

名称と識別子

優先名称
Trichlormethiazide
IUPAC
6-chloro-3-(dichloromethyl)-1,1-dioxo-3,4-dihydro-2H-1λ6,2,4-benzothiadiazine-7-sulfonamide
現地名
トリクロロメチアジド
英語名
Trichlormethiazide
分子式
C8H8Cl3N3O4S2
分子量
380.66

名称と別名

trichlormethiazide133-67-5TrichloromethiazideNaquaMetahydrinTrichlormetazidTrichlormethiazidDiurazidaTrichlorexDiuroralEsmarinFluitran
名称をさらに表示
トリクロロメチアジドプルベックスフルイトランジウレセ6-クロロ-3-(ジクロロメチル)-3,4-ジヒドロ-2H-1,2,4-ベンゾチアジアジン-7-スルホンアミド1,1-ジオキシドヒドロトリクロロチアジドタキオニンアキレチンナトリルクロポリジンアナトラントルカソンジメチアジドスペンジドアポノリントリチアジドニドールオイリノールサルリントリジウリルTRICLORMETIAZIDAFlureseNaquivalNavisNydorNatril
GangesolHydrotrichlorothiazideFlutraNakvaTriclordiurideTrichlormasTriflumenEurinol

データベース識別子

CAS
133-67-5
PubChem CID

物性

構造計算による物性

XLogP
0.6
極性表面積
135 Ų
水素結合供与体数
3
水素結合受容体数
7
回転可能結合数
2
重原子数
20
形式電荷
0
複雑度
571

実験および物理化学的性質

LogP · 3 件

log Kow = 1.00

0.7

0.64

OdorODORLESS OR HAS SLIGHT CHARACTERISTIC ODOR
Color/Form · 2 件

CRYSTALS FROM METHANOL + ACETONE + WATER

WHITE, CRYSTALLINE POWDER

Solubility · 3 件

@ 25 °C: 0.8 MG/ML IN WATER; 21 MG/ML IN ETHANOL; 60 MG/ML IN METHANOL

1 G SOL IN ABOUT 10 ML ACETONE, 50 ML ALCOHOL, 5000 ML CHLOROFORM

4.15e-01 g/L

Human Drugs · 4 件

Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Thiazide Diuretics

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Animal DrugsFDA approved animal drugs -> Active ingredient
DecompositionWhen heated to decomposition it emits very toxic fumes such as sulfoxides, /hydrogen chloride/, and nitroxides.
Physical DescriptionSolid
Stability/Shelf LifeLIGHT-SENSITIVE, BUT STABLE IN AIR & HEAT

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 5 件

This chemical does not meet GHS hazard criteria for 2.4% (1 of 41) of reports.

Danger

H317 (95.1%): May cause an allergic skin reaction [Warning Sensitization, Skin]

P233, P260, P261, P271, P272, P280, P284, P302+P352, P304+P340, P321, P333+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 41 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory InformationTrichlormethiazide: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(dichloromethyl)-3,4-dihydro-, 1,1-dioxide: Human health tier I assessment
FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Hazard Classes and CategoriesSkin Sens. 1 (95.1%)

安全と保護具

Storage ConditionsTrichlormethiazide tablets should be stored in well-closed containers at a temperature less than 40 °C, preferably between 15-30 °C.
Disposal Methods · 1 件

化学と産業

薬理情報

ATC Code · 2 件

C - Cardiovascular system

QC - Cardiovascular system

Pharmacodynamics · 1 件

Trichloromethiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Trichloromethiazide has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomer-ulonephritis, and chronic renal failure. Trichloromethiazide is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Like other thiazides, Trichloromethiazide promotes water loss from the body (diuretics). They inhibit Na<sup>+</sup>/Cl<sup>-</sup> reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.

Mechanism of Action · 6 件

Trichlormethiazide seemingly appears to inhibit the active reabsorption of chloride in the ascending loop of Henle. Additionally, it may also do the same for sodium. These actions subsequently alter electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis. As a diuretic, Trichloromethiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like Trichloromethiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of Trichloromethiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.

関連反応

0 件
反応記録を作成
関連する反応はまだありません

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
5560
DTXSID
DTXSID7023699
ChEMBL
CHEMBL1054
ChEBI
CHEBI:9683
UNII
Q58C92TUN0
EC Number
205-118-8
Dissociation Constants · 2 件

8.6

PKA: 8.6

Other Experimental PropertiesDECOMP AT 266-273 °C, ALSO REPORTED AS 248-250 °C

物理化学的性質

融点
248 · 248-250℃
沸点
631.3 · 631.3±65.0 °C(Predicted)
比重(密度)
1.748 · 1.748
屈折率
1.6 · 1.6000 (estimate)
貯蔵温度
Keep in dark place,Inert atmosphere,Room temperature
溶解性
DMSO(微量)、メタノール(微量)
外見
個体
酸解離定数(Pka)
6.9 · pKa 6.9(acetone/H2O) (Uncertain)
色
ホワイトからオフホワイト
Merck
14 · 14,9624
主な用途
医薬品(低分子化合物)
InChI
1S/C8H8Cl3N3O4S2/c9-3-1-4-6(2-5(3)19(12,15)16)20(17,18)14-8(13-4)7(10)11/h1-2,7-8,13-14H,(H2,12,15,16)
InChIKey
LMJSLTNSBFUCMU-UHFFFAOYSA-N
SMILES
NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C(Cl)Cl)cc1Cl
CAS データベース
133 · 133-67-5(CAS DataBase Reference)
EPAの化学物質情報
Trichlormethiazide (133-67-5)

化学的性質

化学的特性Trichlormethiazide occurs as a white or practically white, crystalline powder and may have a slight characteristic odor.

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

毒性情報

Interactions · 5 件

MANY DIABETIC PATIENTS REGULATED BY CHLORPROPAMIDE OR OTHER SULFONYLUREAS EXHIBIT IMPAIRED DIABETIC CONTROL WHEN ANY THIAZIDE DIURETIC IS ADDED TO DRUG REGIMEN. /THIAZIDE DIURETICS/

...DRUGS SUCH AS...THIAZIDE DIURETICS...WHICH INCR URINARY PH, MAY SERVE TO INCR LIPID SOLUBILITY & TUBULAR REABSORPTION OF QUINIDINE & THUS PROLONG ITS THERAPEUTIC EFFECTS. /THIAZIDE DIURETICS/

...THIAZIDE DIURETICS ENHANCE CARDIOTOXIC & NEUROTOXIC EFFECTS OF LITHIUM & THESE DRUGS SHOULD NOT BE ADMINISTERED CONCURRENTLY. /THIAZIDES/

THIAZIDES ENHANCE ANTIHYPERTENSIVE ACTION OF GUANETHIDINE, ALLOWING DOSE OF GUANETHIDINE TO BE REDUCED & DECR INCIDENCE OF ADVERSE REACTIONS, PARTICULARLY ORTHOSTATIC & EXERCISE-ASSOC HYPOTENSION. /THIAZIDES/

For more Interactions (Complete) data for TRICHLORMETHIAZIDE (24 total), please visit the HSDB record page.

Human Toxicity Excerpts · 2 件

STUDY OF LIVER DAMAGE DURING TREATMENT WITH TRICHLORMETHIAZIDE IN A MIDDLE AGED PATIENT.

May suppress lactation, but compatible /SRP: with breast feeding/. /Thiazide diuretics, from table/

Drug Induced Liver Injury · 4 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Trichlormethiazide

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Non-Human Toxicity ExcerptsHIGH DOSAGE INDUCES HYPERGLYCEMIA & GLYCOSURIA IN RAT & DOG TRIALS.
Antidote and Emergency TreatmentThiazide diuretic overdose should be treated by immediate evacuation of the stomach followed by supportive symptomatic treatment and monitoring of serum electrolyte concentrations and renal function. /Thiazide diuretic/
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Non-Human Toxicity Values · 5 件

LD50 RAT ORAL 5600 MG/KG

LD50 Rat iv 920 mg/kg

LD50 Mouse oral 2600 mg/kg

LD50 Mouse ip 540 mg/kg

LD50 Mouse iv 750 mg/kg

法規制情報

FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

安全データ

wgk
2
tsca
TSCA listed
rtecs
DK8925000
ridadr
UN2811
毒性
LD50 orally in rats: >20000 mg/kg (Goldenthal)
hs_code
2935904000
risk_code
42/43
hazard_code
Xn
safety_code
36
hazard_class
6.1
Hazard Classifications
Resp. Sens. 1Skin Sens. 1
ストレージクラス
11 - Combustible Solids
有毒物質データの
133-67-5(Hazardous Substances Data)

...BENZOTHIADIAZIDES HAVE DIRECT EFFECT ON RENAL TUBULAR TRANSPORT OF SODIUM & CHLORIDE...INDEPENDENT OF ANY EFFECT ON CARBONIC ANHYDRASE. /THIAZIDE DIURETICS/

THIAZIDES INHIBIT REABSORPTION OF SODIUM &...CHLORIDE IN DISTAL SEGMENT. ... AS CLASS...HAVE IMPORTANT ACTION ON EXCRETION OF POTASSIUM THAT RESULTS FROM INCR SECRETION OF CATION BY DISTAL TUBULE. ... GLOMERULAR FILTRATION RATE MAY BE REDUCED BY THIAZIDES, PARTICULARLY WITH IV ADMIN FOR EXPTL PURPOSES. /THIAZIDE DIURETICS/

...MAY DECR EXCRETION OF URIC ACID IN MAN, THUS INCR ITS CONCN IN PLASMA. HYPERURICEMIC EFFECT RESULTS PRIMARILY FROM INHIBITION OF TUBULAR SECRETION OF URATE. ... UNLIKE MOST OTHER NATRIURETIC AGENTS...DECR RENAL EXCRETION OF CALCIUM RELATIVE TO THAT OF SODIUM... /ENHANCE/ EXCRETION OF MAGNESIUM... /THIAZIDE DIURETICS/

NATURE OF CHEM INTERACTION BETWEEN THIAZIDES & SPECIFIC RENAL RECEPTORS RESPONSIBLE FOR CHLORURETIC EFFECT IS NOT KNOWN; NO CRITICAL ENZYMATIC REACTIONS HAVE BEEN IDENTIFIED. /THIAZIDE DIURETICS/

For more Mechanism of Action (Complete) data for TRICHLORMETHIAZIDE (11 total), please visit the HSDB record page.

Biological Half-LifeHalf-life is 2-7 hr. /From table/
MeSH Pharmacological Classification · 3 件

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Agents that promote the excretion of urine through their effects on kidney function.

Agents that inhibit SODIUM CHLORIDE SYMPORTERS. They act as DIURETICS. Excess use is associated with HYPOKALEMIA.

Absorption, Distribution and Excretion · 5 件

Trichlormethiazide is absorbed from the GI tract. Little information is available on the extent of absorption and the fate of trichlormethiazide in the body, although it is believed to be excreted principally as unchanged drug in urine.

MOST CMPD ARE RAPIDLY EXCRETED WITHIN 3-6 HR. /THIAZIDE DIURETICS/

DIURESIS OCCURS WITHIN 2 HR, REACHES PEAK IN 6 HR, & LASTS MORE THAN 24 HR.

THIAZIDES ARE ABSORBED FROM GI TRACT & OWE THEIR USEFULNESS LARGELY TO THEIR EFFECTIVENESS BY ORAL ROUTE. ABSORPTION IS RELATIVELY RAPID. MOST AGENTS SHOW DEMONSTRABLE DIURETIC EFFECT WITHIN HR AFTER ORAL ADMIN. /THIAZIDE DIURETICS/

IN GENERAL, THIAZIDES WITH RELATIVELY LONG DURATIONS OF ACTION SHOW PROPORTIONATELY HIGH DEGREE OF BINDING TO PLASMA PROTEINS & ARE REABSORBED... BY RENAL TUBULES. ... DRUG PASSES READILY THROUGH PLACENTAL BARRIER TO FETUS. ALL THIAZIDES PROBABLY UNDERGO ACTIVE SECRETION IN PROXIMAL TUBULE. /THIAZIDE DIURETICS/

Cellular LocationsCytoplasm
Metabolite PathwaysTrichlormethiazide Action Pathway

用途と製造

Uses · 2 件

THERAP CAT: Diuretic, antihypertensive; THERAP CAT (VET): Diuretic.

MEDICATION

Methods of Manufacturing · 3 件

DESTEVENS ET AL, EXPERIENTIA 16, 113 (1960); SHERLOCK ET AL, EXPERIENTIA 16 184 (1960).

BY REACTING 4-AMINO-6-CHLORO-M-BENZENE-DISULFONAMIDE WITH DICHLOROACETALDEHYDE, OR ACETAL THEREOF, IN SUITABLE CONDENSATION ENVIRONMENT. US PATENTS 3,163,645 & 3,264,292.

Chloral + 5-chloroaniline-2,4-disulfonamide (carbonyl condensation).

Formulations/Preparations · 2 件

TABLETS NF: 2 & 4 MG.

METAHYDRIN, NAQUA. MARKET PREPN (TABLETS) 2 & 4 MG.

Use ClassificationPharmaceuticals
General Manufacturing Information2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(dichloromethyl)-3,4-dihydro-, 1,1-dioxide: ACTIVE
応用分野 · 2 件

用途チアジド系利尿薬遠位尿細管のNa+の再吸収を抑制して利尿を生じさせる

使用Trichlormethiazide is a diuretic and anti-hypertensive agent from the benzothiadiazide class which is used in veterinary medicine in cattle, sheep, goats, pigs and horses, at the following therapeutic regimen: a single intramuscular dose of 0.4 mg/kg bw followed by two oral doses of 0.8 mg/kg bw given 12 and 36 hours after the first administration. Trichlormethiazide is also used in humans in the United States as a diuretic and anti-hypertensive substance but not in the European Union. The usual dose is 2 to 4 mg twice a day (i.e. approximately 0.033 to 0.066 mg/kg bw/day).

上流・下流製品情報

上流原料

5クロロ2メチル4イソチアゾリン3オン2,2-ジクロロアセトアルデヒド4-アミノ-6-クロロ-1,3-ベンゼンジスルホンアミド